Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 15, 2023 16:11 UTC |
Jones ErikaSEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022388 · tm236831-4_4seq1.xml · derivative · entry 2 Jones Erika · CIK 0001895913 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-02-12 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:11 UTC |
Jones ErikaSEE REMARKS
|
GrantCommon Stock | 5,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-022388 · tm236831-4_4seq1.xml · nonDerivative · entry 1 Jones Erika · CIK 0001895913 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,150 F1 · shares: The Reporting Person was previously granted performance-based Restricted Stock Units ("RSUs"). The vesting of 35% of the RSUs was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 1,776 RSUs, with the remainder vesting on August 15, 2023, subject to the grantee's continuous service through such vesting date. F1 · price: The Reporting Person was previously granted performance-based Restricted Stock Units ("RSUs"). The vesting of 35% of the RSUs was subject to the achievement of certain performance criteria. As of the transaction date, the performance criteria were met, resulting in the vesting of 1,776 RSUs, with the remainder vesting on August 15, 2023, subject to the grantee's continuous service through such vesting date. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:11 UTC |
Ni FangSEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022389 · tm236831-5_4seq1.xml · derivative · entry 1 Ni Fang · CIK 0001895910 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:10 UTC |
Buck ElizabethCHIEF SCIENTIFIC OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022386 · tm236831-2_4seq1.xml · derivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:10 UTC |
Epstein David M.Director · SEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 420,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022387 · tm236831-3_4seq1.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:12 UTC |
Yurasov SergeyCHIEF MEDICAL OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022391 · tm236831-6_4seq1.xml · derivative · entry 1 Yurasov Sergey · CIK 0001686295 · CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 21:10 UTC |
Hatzis-Schoch BrentSEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-23-022383 · tm236831-1_4seq1.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-02-12 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 13, 2024, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 22, 2022 Filed Dec 23, 2022 16:23 UTC |
Ni FangSEE REMARKS
|
PurchaseCommon Stock | 36,363 | $1.28 | $46,595.55 |
DisclosureSEC source: 0001415889-22-012966 · form4-12232022_091226.xml · nonDerivative · entry 2 Ni Fang · CIK 0001895910 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,389 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.23 to $1.3099, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 16:23 UTC |
Ni FangSEE REMARKS
|
PurchaseCommon Stock | 20,000 | $1.29 | $25,770.00 |
DisclosureSEC source: 0001415889-22-012966 · form4-12232022_091226.xml · nonDerivative · entry 1 Ni Fang · CIK 0001895910 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,026 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 02:27 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 7,917 | $1.50 | $11,875.50 |
DisclosureSEC source: 0001209191-22-062074 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,004 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 02:16 UTC |
Velleca Mark A.Director
|
GrantCommon Stock | 8,424 | $1.50 | $12,636.00 |
DisclosureSEC source: 0001415889-22-012797 · form4-12202022_021242.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,157 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 02:15 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 7,167 | $1.50 | $10,750.50 |
DisclosureSEC source: 0001415889-22-012796 · form4-12202022_021201.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,216 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 02:14 UTC |
INGRAM ROBERT ALEXANDERFORMER DIRECTOR
|
GrantCommon Stock | 9,375 | $1.50 | $14,062.50 |
DisclosureSEC source: 0001415889-22-012795 · form4-12202022_021217.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · FORMER DIRECTOR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,854 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 15, 2022. Read SEC document |
| October 31, 2022 Filed Nov 2, 2022 19:10 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 99,801 | $2.25 | $224,911.53 |
DisclosureSEC source: 0000899243-22-034751 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,377,839 Read SEC document |
| October 28, 2022 Filed Oct 31, 2022 19:20 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 172,974 | $2.18 | $376,962.24 |
DisclosureSEC source: 0000899243-22-034543 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,278,038 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 19:20 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 191,678 | $1.87 | $359,223.74 |
DisclosureSEC source: 0000899243-22-034543 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,105,064 Read SEC document |
| October 21, 2022 Filed Oct 25, 2022 20:24 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 87,850 | $1.51 | $132,750.14 |
DisclosureSEC source: 0000899243-22-034121 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,913,386 Read SEC document |
| October 20, 2022 Filed Oct 21, 2022 19:06 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 53,734 | $1.42 | $76,345.27 |
DisclosureSEC source: 0000899243-22-033945 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,825,536 Read SEC document |
| October 19, 2022 Filed Oct 21, 2022 19:06 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 77,689 | $1.32 | $102,774.78 |
DisclosureSEC source: 0000899243-22-033945 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,771,802 Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 21:09 UTC |
Velleca Mark A.Director
|
GrantCommon Stock | 4,294 | $2.62 | $11,250.28 |
DisclosureSEC source: 0001415889-22-009773 · form4-09192022_020914.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,733 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 15, 2022. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 22:39 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 4,532 | $2.62 | $11,873.84 |
DisclosureSEC source: 0001209191-22-050622 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,087 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 15, 2022. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 21:10 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 4,103 | $2.62 | $10,749.86 |
DisclosureSEC source: 0001415889-22-009774 · form4-09192022_020947.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,049 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 15, 2022. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 21:08 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 6,584 | $2.62 | $17,250.08 |
DisclosureSEC source: 0001415889-22-009771 · form4-09192022_020900.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,479 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 15, 2022. Read SEC document |
| June 29, 2022 Filed Jun 30, 2022 16:05 UTC |
Ni FangSEE REMARKS
|
PurchaseCommon Stock | 25,000 | $2.44 | $61,017.50 |
DisclosureSEC source: 0001415889-22-007099 · form4-06302022_010621.xml · nonDerivative · entry 1 Ni Fang · CIK 0001895910 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,026 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.394 to $2.5599, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 20:35 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 5,850 | $2.03 | $11,875.50 |
DisclosureSEC source: 0001209191-22-037904 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,555 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 20:27 UTC |
Velleca Mark A.Director
|
GrantCommon Stock | 5,542 | $2.03 | $11,250.26 |
DisclosureSEC source: 0001415889-22-006741 · form4-06172022_010656.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,439 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 20:26 UTC |
DIXON WENDY LDirector
|
GrantCommon Stock | 4,060 | $2.03 | $8,241.80 |
DisclosureSEC source: 0001415889-22-006740 · form4-06172022_010651.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,060 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022. Read SEC document |
| June 17, 2022 Filed Jun 17, 2022 20:25 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 8,498 | $2.03 | $17,250.94 |
DisclosureSEC source: 0001415889-22-006739 · form4-06172022_010601.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,895 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022. Read SEC document |
| June 17, 2022 Filed Jun 30, 2022 20:07 UTC Amendment |
DIXON WENDY LDirector
|
GrantCommon Stock | 4,946 | $2.03 | $10,040.38 |
DisclosureSEC source: 0001415889-22-007101 · form4a-06302022_010603.xml · nonDerivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,946 F1 · kind: These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:08 UTC |
Behbahani AliDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001209191-22-036465 · doc4.xml · derivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:09 UTC |
Mayweg AlexanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006520 · form4-06132022_040616.xml · derivative · entry 1 Mayweg Alexander · CIK 0001786260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:08 UTC |
Velleca Mark A.Director
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006519 · form4-06132022_040655.xml · derivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:05 UTC |
Dhingra KapilDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006517 · form4-06132022_040601.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:06 UTC |
Shah Rajeev M.Director
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001104659-22-070650 · tm2218344-1_4seq1.xml · derivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F2 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. F1 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. F2 · ownership.nature: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. F3 · ownership.nature: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the shares for the benefit of the Fund and the Nexus Fund. The Reporting Person is obligated to turn over to the Adviser any net cash or stock received as compensation from the Issuer, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the common stock. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:06 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006518 · form4-06132022_040607.xml · derivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:04 UTC |
Menzel Garry EDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006516 · form4-06132022_040607.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:02 UTC |
Kulkarni SamarthDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006515 · form4-06132022_040646.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 23:01 UTC |
DIXON WENDY LDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-22-006514 · form4-06132022_040639.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 7, 2023 or (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| April 28, 2022 Filed Apr 29, 2022 14:50 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 255,711 | $2.57 | $657,867.69 |
DisclosureSEC source: 0000899243-22-016006 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,694,113 Read SEC document |
| April 27, 2022 Filed Apr 29, 2022 14:50 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 150,000 | $2.66 | $399,480.00 |
DisclosureSEC source: 0000899243-22-016006 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,438,402 Read SEC document |
| April 19, 2022 Filed Apr 20, 2022 16:56 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 150,000 | $3.24 | $486,645.00 |
DisclosureSEC source: 0000899243-22-015145 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,288,402 Read SEC document |
| April 18, 2022 Filed Apr 20, 2022 16:56 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 150,000 | $3.29 | $493,935.00 |
DisclosureSEC source: 0000899243-22-015145 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,138,402 Read SEC document |
| April 13, 2022 Filed Apr 14, 2022 16:09 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 102,556 | $3.57 | $366,217.22 |
DisclosureSEC source: 0000899243-22-014768 · doc4.xml · nonDerivative · entry 2 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,988,402 Read SEC document |
| April 12, 2022 Filed Apr 14, 2022 16:09 UTC |
BIOTECH GROWTH N V10% owner
BB BIOTECH AG10% owner
|
PurchaseCommon Stock | 150,000 | $3.42 | $513,600.00 |
DisclosureSEC source: 0000899243-22-014768 · doc4.xml · nonDerivative · entry 1 BIOTECH GROWTH N V · CIK 0001259869 · 10% owner BB BIOTECH AG · CIK 0000924223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,885,846 Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:16 UTC |
DIXON WENDY LDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001415889-22-003940 · form4-04072022_010423.xml · derivative · entry 1 DIXON WENDY L · CIK 0001202283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-04-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment vesting on May 6, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 18, 2022 Filed Mar 18, 2022 20:15 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 4,346 | $3.02 | $13,124.92 |
DisclosureSEC source: 0001209191-22-020012 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,705 F1 · kind: These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022. Read SEC document |
| March 18, 2022 Filed Mar 18, 2022 20:05 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 5,795 | $3.02 | $17,500.90 |
DisclosureSEC source: 0001415889-22-003184 · form4-03182022_040302.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,397 F1 · kind: These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022. Read SEC document |
| March 18, 2022 Filed Mar 18, 2022 20:05 UTC |
Velleca Mark A.Director
|
GrantCommon Stock | 2,897 | $3.02 | $8,748.94 |
DisclosureSEC source: 0001415889-22-003185 · form4-03182022_040310.xml · nonDerivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,897 F1 · kind: These shares were issued in accordance with the Issuer's Second Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 17, 2022. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:17 UTC |
Jones ErikaSEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 20,300 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001515 · form4-02172022_010228.xml · derivative · entry 2 Jones Erika · CIK 0001895913 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,300 Underlying: Common Stock · 20,300 shares Expires 2032-02-14 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:17 UTC |
Jones ErikaSEE REMARKS
|
GrantCommon Stock | 5,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001515 · form4-02172022_010228.xml · nonDerivative · entry 1 Jones Erika · CIK 0001895913 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,075 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 35% on the 9 month anniversary of February 15, 2022 (the "Vesting Commencement Date"), 35% on the 18 month anniversary of the Vesting Commencement Date, and the remaining 30% on the 27 month anniversary of the Vesting Commencement Date. F1 · price: Represents a grant of Restricted Stock Units ("RSUs") under the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: 35% on the 9 month anniversary of February 15, 2022 (the "Vesting Commencement Date"), 35% on the 18 month anniversary of the Vesting Commencement Date, and the remaining 30% on the 27 month anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.